88,898 Shares in Kenvue Inc. $KVUE Acquired by Quantbot Technologies LP

Quantbot Technologies LP bought a new stake in Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 88,898 shares of the company’s stock, valued at approximately $1,699,000.

Other institutional investors also recently added to or reduced their stakes in the company. Johnson Financial Group Inc. acquired a new position in Kenvue during the 2nd quarter worth approximately $26,000. CoreCap Advisors LLC raised its holdings in shares of Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after purchasing an additional 591 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in shares of Kenvue during the 4th quarter worth $26,000. Physician Wealth Advisors Inc. grew its stake in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares in the last quarter. Finally, MV Capital Management Inc. purchased a new position in Kenvue in the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 1.8%

KVUE stock opened at $19.41 on Tuesday. The company has a market cap of $37.27 billion, a price-to-earnings ratio of 22.30, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47. The company has a fifty day moving average price of $19.08 and a 200 day moving average price of $18.21. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $21.63.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same quarter in the prior year, the firm posted $0.29 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, August 12th. This represents a $0.84 annualized dividend and a yield of 4.3%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is currently 96.55%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. UBS Group cut their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Barclays raised their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Three equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.